Worldwide nanotechnology development
and application have fueled
many scientific advances, but technophilic expectations and technophobic
demands must be counterbalanced in parallel. Some of the burning issues
today are the following: (1) Where is nano today? (2) How good are
the communication and investment networks between academia/research
and governments? (3) Is there any spotlight application for nanotechnology?
Nanomedicine is a particular arm of nanotechnology within the healthcare
landscape, focused on diagnosis, treatment, and monitoring of emerging
(such as coronavirus disease 2019, COVID-19) and contemporary (including
diabetes, cardiovascular diseases, neurodegenerative disorders, and
cancer) diseases. However, it may only represent the bright side of
the coin. In fact, in the recent past, the concept of nanotoxicology
has emerged to address the dark shadows of nanomedicine. The nanomedicine
field requires more nanotoxicological studies to identify undesirable
effects and guarantee safety. Here, we provide an overall perspective
on nanomedicine and nanotoxicology as central pieces of the giant
puzzle of nanotechnology. First, the impact of nanotechnology on education
and research is highlighted, followed by market trends and scientific
output tendencies. In the next section, the nanomedicine and nanotoxicology
dilemma is addressed through the interplay of in silico, in vitro, and in vivo models
with the support of omics and microfluidic approaches.
Lastly, a reflection on the regulatory issues and clinical trials
is provided. Finally, some conclusions and future perspectives are
proposed for a clearer and safer translation of nanomedicines from
the bench to the bedside.